Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Noncompartmental Analysis: Mean Transit, Absorption and Dissolution Time01:02

Noncompartmental Analysis: Mean Transit, Absorption and Dissolution Time

When drugs are administered extravascularly, a comprehensive evaluation through noncompartmental analysis becomes imperative. This analytical approach considers various parameters that play a crucial role in understanding the pharmacokinetics of these drugs.
One of the key parameters is the mean transit time (MTT), which refers to the total duration required for drug molecules to transit through the body. MTT is determined by calculating the ratio of the area under the moment curve to the area...
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance01:23

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Modified-Release Drug Delivery Systems: Drug Release Characteristics01:22

Modified-Release Drug Delivery Systems: Drug Release Characteristics

Drug release from modified-release dosage forms is designed to achieve specific therapeutic effects by controlling the rate and extent of drug release. The classification of these drug release systems is based on key pharmacokinetic assumptions: drug disposition follows first-order kinetics, drug release is the rate-limiting step in absorption, and the released drug is rapidly and completely absorbed.There are four major models of drug release patterns. The first model is the slow zero-order...
Nonlinear Pharmacokinetics: Drug Elimination for IV Bolus Injection00:59

Nonlinear Pharmacokinetics: Drug Elimination for IV Bolus Injection

In pharmacokinetics, the elimination rate of a drug following a capacity-limited model is primarily controlled by two parameters: Vmax and KM. These parameters are crucial in how the drug behaves inside the body after administration.
Following the administration of a single intravenous (IV) bolus injection, we can determine the concentration of the drug in the plasma at any given time. This calculation is achieved using a specific equation that integrates the values of Vmax and KM.
We can also...
Compartment Models: Two-Compartment Model01:20

Compartment Models: Two-Compartment Model

The two-compartment model divides the body into central and peripheral compartments to account for varying blood perfusion rates among organs and tissues, affecting drug distribution. The central compartment includes blood and highly perfused tissues with rapid drug distribution, while the peripheral compartment contains tissues with slower drug distribution. After a single IV bolus dose, the drug concentration is high in plasma and low in tissues. The drug distribution between compartments...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Small biopsy diagnosis of anterior mediastinal masses: histologic, immunohistochemical, and molecular considerations.

Mediastinum (Hong Kong, China)·2026
Same author

Utilizing Dynamic Liquid Crystal Elastomer Dressings to Enhance Early Dermal Wound Closure.

Laryngoscope investigative otolaryngology·2026
Same author

Reply to 'Boundary issues for multidimensional frameworks of representation'.

Nature reviews. Neuroscience·2026
Same author

A Long-Needed Assist for Radiology Chart Review: An Early Career Perspective.

Radiology·2026
Same author

Favorable one-year outcomes despite residual fascial tension after ventral hernia repair with transversus abdominis release.

Hernia : the journal of hernias and abdominal wall surgery·2026
Same author

Diversity-driven biochemical survey reveals widespread dimerization throughout the rubisco superfamily.

Nature communications·2026

Related Experiment Video

Updated: May 26, 2026

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

Provider variation in fast track treatment time.

Melissa L McCarthy1, Ru Ding, Jesse M Pines

  • 1Department of Health Policy, George Washington University, Washington, DC 21209, USA. melissa.mccarthy@gwumc.edu

Medical Care
|December 21, 2011
PubMed
Summary

Fast track (FT) treatment times varied significantly among healthcare providers, with some taking 1.4 to 2.6 times longer than others. Provider and clinical factors explained most of this variation in emergency department care.

More Related Videos

Upper-extremity Approach for Secondary Access in Transfemoral Transcatheter Aortic Valve Implantation
06:04

Upper-extremity Approach for Secondary Access in Transfemoral Transcatheter Aortic Valve Implantation

Published on: August 8, 2025

Related Experiment Videos

Last Updated: May 26, 2026

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

Upper-extremity Approach for Secondary Access in Transfemoral Transcatheter Aortic Valve Implantation
06:04

Upper-extremity Approach for Secondary Access in Transfemoral Transcatheter Aortic Valve Implantation

Published on: August 8, 2025

Area of Science:

  • Emergency Medicine
  • Healthcare Operations
  • Clinical Efficiency

Background:

  • Fast track (FT) protocols aim to expedite care for less acute patients in emergency departments (EDs).
  • Significant variations in treatment times among providers can impact patient flow and resource allocation within EDs.

Purpose of the Study:

  • To quantify the extent of variation in FT treatment times among different healthcare providers.
  • To identify factors contributing to this observed variation in FT treatment duration.

Main Methods:

  • A retrospective cohort study analyzed 105,783 FT visits across 3 EDs over 3 years.
  • Median treatment times were calculated for 80 primary providers and 109 nurses.
  • Hierarchical linear regression controlled for patient, clinical, temporal, and ED demand characteristics.

Main Results:

  • Median FT treatment times ranged from 48 to 134 minutes across sites.
  • Provider FT treatment times at the 90th percentile were 1.4 to 2.6 times longer than at the 10th percentile.
  • Provider and clinical factors accounted for more variation than patient, ED demand, or temporal factors.

Conclusions:

  • Clinically significant differences in FT treatment times exist among providers, even within the same ED environment.
  • Further investigation is warranted to understand the drivers of this substantial provider-level variation in FT treatment times.